Introduction {#S0001}
============

Colon cancer is a very serious clinical problem. It is the second most frequent cause of cancer mortality in the world\'s more developed countries. Over the past 15 years, researchers have submitted a lot of evidence to show that colorectal cancer (CRC) is a progressive genetic disease \[[@CIT0001]\]. It is now clear that neoplasm development is a complex multistep process. Multiple molecular pathways exist in colorectal tumourgenesis in addition to the classic suppressor and mutator mechanisms \[[@CIT0002]\]. Despite the wealth of knowledge that exists regarding the genetic background of this disease, there is still a need to look for some missing points in the development of this tumour.

The characterisation of splicing deregulation in cancer may lead to greater comprehension of malignant transformation, especially as specific alterations in splicing patterns exist in cancer-associated genes. Many of these changes may play a functional role in transformation, motion and metastasis of tumour cells \[[@CIT0003], [@CIT0004]\]. Alternative splicing variants of those genes may have prognostic or predictive values that could facilitate diagnostic and/or treatment procedures. Consequently, experimental research focuses on splice variants appearing during cancerogenesis, which could potentially become new molecular markers \[[@CIT0005]\]. Abnormal splicing of several genes has been observed in tumours of colorectal origin, e.g. *CD44* \[[@CIT0006], [@CIT0007]\], *MUC2* \[[@CIT0008]\], *SRF* \[[@CIT0009]\], *NCAM* \[[@CIT0010]\], *MLH*, *MSH* \[[@CIT0011]\] and members of the Wnt pathway \[[@CIT0012]\]. There is evidence that *FJ 194940.1* gene variants play an important role in colon tumourigenesis \[[@CIT0013]\].

The *FJ 194940.1* gene is located on chromosome 1, region 224792167-224794166. In normal human tissues, this chromosome region is expressed as the AK055856 transcript only in the kidney. Probably during cancerogenesis, integration of an additional copy of rv_001141 changes this transcription region. The new transcript has 921 bp and encodes a protein that contains an integrase core domain similar to the human protein EAW69787. Genomic DNA of the new transcript spans 3518 bp and consists of five exons and four introns \[[@CIT0014]\].

Studies have shown that the *FJ 194940.1* gene may be a potential molecular marker of cancer development and progression \[[@CIT0015]--[@CIT0017]\]. Some of these indicated that the expression of elements of the *FJ 194940.1* gene is associated with clinical stages of colon cancer. Expression of the whole exon V of *FJ 194940.1* as well as fragments of exon IV and VI was found at advanced stages of cancer development \[[@CIT0018]\]. This observation was further confirmed by quantitative analysis in the same colon cancer cases. A high expression level of this *FJ 194940.1* transcript fragment was found in patients with metastases to lymph nodes and distant metastases, and in cases with vessel invasion and absence of lymphocytes in tumour tissue. The level of expression was associated with shorter survival time \[[@CIT0016]\]. Interestingly, the expression of those elements was not regular \[[@CIT0018]\].

A forward preliminary assay has taken into consideration the whole transcript of the *FJ 194940.1* gene. This report stated that *FJ 194940.1* undergoes alternative splicing. Exon V was irregularly observed in 30 investigated colon cancer cases but its expression was not significantly connected with any clinicopathological features \[[@CIT0014]\].

Results obtained by Bartczak *et al*. \[[@CIT0013]\] have confirmed that *FJ 194940.1* undergoes alternative splicing. Expressions of exons and exon-exon junctions were not associated with any clinicopathological features in colon cancer. On the other hand, exon V, the object of the present study, was an element of the part B transcript (comprising exon IV, V as well as III/IV and IV/V exon-exon junction). The presence of part B expression was connected with cases of low-grade malignancy, which correlated with better prognosis for patients \[[@CIT0013]\]. Importantly, the expression of exon V was found in all of the investigated samples \[[@CIT0013]\].

The discrepancies described regarding the potential prognostic value of *FJ 194940.1* gene expression in colon cancer, as well as the precursory character of the mentioned study, indicate the need for a more searching investigation.

The study presented here is a follow-up to the Bartczak *et al*. experiment \[[@CIT0013]\], where in exon V expression was detected in all examined samples. Additionally, this exon is a part of the *FJ 194940.1* transcript fragment that was studied by Balcerczak E. *et al*. in 2003 \[[@CIT0018]\] and Balcerczak M. *et al*. in 2007 \[[@CIT0016]\]. The aim of this presented study was to investigate the exon V *FJ 194940.1* gene expression level, quantified by real-time PCR, in a series of 102 colon cancer cases, and evaluate its utility as a prognostic marker in colon cancer patients.

Material and methods {#S0002}
====================

Materials {#S20003}
---------

Tissue specimens of colorectal cancer were obtained from the Oncological Centre of Lodz, Poland. CRC was diagnosed by histopathological examination using established clinical criteria (TNM classification by Jass with latest revision Cancer Staging Manual by AJCC, 1997) at the Department of Pathology, Medical University of Lodz, Poland. Tissue samples from 102 patients were frozen in liquid nitrogen immediately after surgery and stored at --80°C until further examination. The characteristics of the examined population are shown in [Table 1](#T0001){ref-type="table"}.

###### 

Comparison of *FJ 194940.1* exon V expression level with clinicopathological parameters

  Feature                                      *n*     Median   Minimum   Maximum   Lower quartile   Upper quartile   *p* value
  --------------------------------- ---------- ------- -------- --------- --------- ---------------- ---------------- -----------
  Gender                            female     44      11.21    0.10      1831.97   3.05             42.59            0.2955
  male                              35         19.17   0.05     329.69    7.34      42.66                             
  Family history                    negative   69      16.83    0.10      1831.97   9.04             83.99            0.9003
  positive                          10         17.87   0.38     149.63    4.07      30.21                             
  Tumour location                   rectum     30      13.29    0.16      1832.97   5.22             40.78            0.9672
  colon                             48         16.70   0.05     1699.60   2.87      48.53                             
  Histological type                 tubular    69      16.83    0.05      1831.97   4.01             44.40            0.5905
  mucinous                          10         11.35   2.73     105.44    7.68      19.17                             
  Histological grade                G1 or G2   57      16.83    0.10      1831.97   5.63             55.32            0.2281
  G3                                21         12.66   0.05     1699.60   2.81      25.49                             
  Invasion of the intestinal wall   T1 or T2   21      16.58    0.10      1831.97   6.81             35.99            0.9823
  T3 or T4                          58         16.03   0.05     1699.60   4.01      44.40                             
  Node involvement                  N0         41      16.58    0.10      1831.97   6.81             42.66            0.7095
  pN1 or pN2                        34         17.04   0.05     1699.60   4.01      44.40                             
  Distant metastasis                M0         61      16.83    0.05      1831.97   5.63             42.66            0.2848
  M1                                18         8.06    0.16     1699.60   2.16      39.57                             
  pTNM stage                        I or II    40      15.90    0.10      1831.97   6.22             39.32            0.7611
  III or IV                         39         16.83   0.05     1699.60   2.81      44.40                             
  Lymphocytic infiltration          absent     43      9.47     0.16      1831.97   3.17             55.32            0.4245
  present                           35         18.14   0.05     1699.60   5.04      42.44                             
  Vessel invasion                   absent     28      26.69    0.55      1831.97   9.00             60.59            0.0697
  present                           51         12.66   0.05     1699.60   2.94      40.78                             

All experiments were carried out with local ethical committee approval (No. RNN/214/00) and patients' informed consent.

RNA isolation {#S20004}
-------------

Total RNA isolation was performed in accordance with the protocol enclosed in the Total RNA Prep Plus Minicolumn Kit (*A&A Biotechnology*, *Poland*). The method is based on RNA isolation methodology developed earlier by Chomczynski and Sacchi, 1987 \[[@CIT0020]\]. RNA concentration was determined spectrophotometrically. The isolated RNA had an A260/280 ratio of 1.6--1.8. Purified RNA samples were stored at --80°C.

cDNA synthesis {#S20005}
--------------

RT-PCR reaction was carried out using Enhanced Avian HS RT-PCR Kit, Sigma, according to the manufacturer\'s protocol. The cDNA was used immediately or stored at --20°C. Presence of cDNA in each sample was checked by PCR amplification of *β-actin*. Only samples showing the PCR product of this housekeeping gene were included in further tests.

Real-time PCR {#S20006}
-------------

The amount of *FJ 194940.1* transcript containing exon V was analysed by means of real-time PCR.

Amplification reactions were performed using Rotor-Gene 6000 (Corbet) and SYBR Green Jump Start Tag ReadyMix^TM^ (Sigma) according to the manufacturer\'s instructions.

The primer set CTCTCTTGCTGAAATGCTGG (forward) and GGCCCAGGCTTTAAACTATA (reverse) and reaction conditions used in the assay were described earlier \[[@CIT0014]\]. The 25 µl reactions consisted of 12.5 µl of JumpStart Taq ReadyMix, 0.5 µl of forward primer (final concentration 0.28 µl), 0.5 µl of reverse primer (final concentration 0.28 µl), 1.5 µl of magnesium chloride (final concentration 3 µl), and 2.5 µl of temple cDNA or sterile water. The thermal cycling conditions were 7 minutes at 95°C, followed by 40 cycles of 60 seconds at 97°C, 60 seconds at 60°C, and 60 seconds at 72°C. Experiments were performed in duplicate to ensure reproducibility of the technique. At the end of each reaction, the threshold was manually set at the level reflecting the best kinetic PCR parameters, the same for all analysed samples. Ct was determined and melting curves were acquired and analysed.

As a reference, the expression of the *b-actin* gene was quantified for each sample using the 5'-GTGGGGCGCCCCAGGCACCA-3' (forward), 5'-CTCCTTAATGTCACGCACGATTTC-3' (reverse) primer set. The reactions for *FJ 194940.1* exon V and *β-actin* were carried out in separate tubes. The 2^--ΔΔ^ method invented by Livak and Schmittgen \[[@CIT0020]\] was used to calculate relative changes in gene expression determined from real-time quantitative PCR experiments. Real-time PCR assay has a 100% amplification efficiency for both genes and was therefore used in the 2(ΔΔC(T)) method.

Statistical analysis {#S20007}
--------------------

STATISTICA 9.1 (StatSoft, Inc., 2010) was used for statistical analyses. The collected quantitative data were tested to check for conformity with a normal distribution on the basis of the Shapiro-Wilk test. Due to a lack of conformity in distributions with normal distribution in every subgroup of patients compared, the statistical analysis of the obtained results employed the nonparametric Mann-Whitney U test.

Dependences between clinicopathological characteristics, *FJ 194940.1* exon V expression levels and overall survival in the entire population of 79 patients were estimated using the Kaplan-Meier estimator (univariate analysis). Overall survival was determined as the interval between surgery and death. Median overall survival time was 65 months (minimum 1 month, maximum 110 months). The log-rank test was used to test for differences in time-to-death distribution.

A Cox proportional hazard regression model (multivariate analysis) was created to identify the independent prognostic factors. A *p*-value \< 0.05 was assumed as significant in all conducted tests.

Results {#S0008}
=======

Expression analysis was successful in 87 out of 102 cases of colorectal carcinomas taken for analysis. In 15 of the examined samples, no PCR product was obtained for the housekeeping gene, despite RNA being detected in those cases by spectrophotometric analysis. A possible explanation for this is polymerase chain reaction inhibition, for which there are three likely mechanisms:direct interaction between inhibitors and polymerase;interaction of the inhibitor with the DNA; orinteraction with the polymerase during primer extension \[[@CIT0021]\].

It is also possible that the PCR is inhibited by reverse transcriptase \[[@CIT0022]\]. Subsequently, we rejected eight cases as being outliers and extremes.

The analysed population consisted of 44 women and 35 men. Most cases had a negative family history. No statistically significant correlation was observed between exon V expression level and gender or family history (*p* = 0.2955, *p* = 0.9003, respectively).

The majority of the investigated tumours were located in the colon. There was no significant correlation between exon V expression level and tumour location (*p* = 0.9672).

Previously, all examined cases had been histologically classified as tubular or mucinous type. Sixty-nine cases represent tubular type. There was no significant correlation between exon V expression level and histological type of tumour (*p* = 0.5905).

The exon V expression level was not significantly related to the grade of histological malignancy of the cancer (*p* = 0.2281).

*FJ 194940.1* exon V expression level was compared with several clinicopathological parameters such as depth of tumour invasion (T), presence of lymph node (N) and distant metastases (M), or pTNM stage. There was no significant correlation between the expression level and the comparison parameters (*p* = 0.9823, 0.7095, 0.2848, 0.7611, respectively).

No statistically significant correlation has been found between the exon V expression level and the presence of lymphocytes in tumour tissue (*p* = 0.4245). Furthermore, there was no statistically significant correlation between the presence of vessel invasion and the exon V expression level despite a visible tendency towards a lower expression level in a subgroup of cases with vessel invasion presence (*p* = 0.0697).

All of the findings described above are summarised in [Table 1](#T0001){ref-type="table"}.

Exon V expression level and survival time {#S20009}
-----------------------------------------

To carry out a survival analysis, the entire group was divided into two subgroups based on a median value of the exon V expression level in the entire investigated group. The subgroup described as "low" comprised cases having an expression level lower than the median. The subgroup described as "high" comprised cases showing an expression level equal to or higher than the median. There was a statistically significant difference in survival time probability when comparing the two subgroups (*p* = 0.0315). Patients with a high exon V expression level show a longer survival time than patients with a low exon V expression level ([Fig. 1](#F0001){ref-type="fig"}).

![Overall survival probability in the patient groups with relatively high and relatively low exon V expression levels](WO-17-20404-g001){#F0001}

The impact of clinicopathological features on survival time was also analysed. Among these, histological grade, invasion of the intestinal wall, node involvement, distant metastasis, pTNM stage and venous invasion were each significantly related to survival time (univariate analysis, [Table 2](#T0002){ref-type="table"}). Absence of lymph node involvement (N0, *p* = 0.0008), absence of distant metastasis (M0, *p* = 0.0000), and lower pTNM stage (pTNM I pTNM II, *p* = 0.0012) were significantly associated with a longer survival time. Moreover, trends were observed toward a longer survival time in the subgroup of cases of lower malignancy (G1 or G2 stage, *p* = 0.0673) and lower depth of tumour invasion (T1, T2 *p* = 0.0562). Likewise, absence of vessel invasion was associated with higher overall survival probability (*p* = 0.0582). All of the observed dependences are presented in [Table 2](#T0002){ref-type="table"}.

###### 

Overall survival analysis according to clinicopathological features and exon V expression level (univariate analysis)

  Feature                                       Number of deaths (%)   *p* value (log-rank test)
  --------------------------------- ----------- ---------------------- ---------------------------
  Gender                            female      22 (50.0)              0.3137
  male                              19 (55.9)                          
  Family history                    negative    37 (54.4)              0.3924
  positive                          4 (40.0)                           
  Tumour localization               rectum      17 (56.7)              0.9710
  colon                             24 (51.1)                          
  Histological type                 tubular     36 (52.9)              0.9789
  mucinous                          5 (50.0)                           
  Histological grade                G1 or G2    26 (46.4)              0.0673
  G3                                14 (66.7)                          
  Invasion of the intestinal wall   T1 or T2    8 (38.1)               0.0562
  T3 or T4                          33 (57.9)                          
  Node involvement                  N0          15 (36.6)              0.0008
  N1 or N2                          23 (69.7)                          
  Distant metastasis                M0          24 (40.0)              0.0000
  M1                                17 (94.4)                          
  pTNM stage                        I or II     15 (37.5)              0.0012
  III or IV                         26 (68.4)                          
  Lymphocytic infiltration          absent      25 (58.1)              0.2299
  present                           15 (44.1)                          
  Vessel invasion                   absent      11 (39.3)              0.0582
  present                           30 (60.0)                          
  Exon V expression level           high        14 (37.8)              0.0315
  low                               26 (66.7)                          

Variables with a *p* value of less than 0.1 in univariate analysis were chosen to create a Cox regression model. As histological grade, invasion of the intestinal wall, node involvement, distant metastasis, and vessel invasion showed significant correlation with pTNM stage ([Table 3](#T0003){ref-type="table"}), only pTNM stage and exon V expression level were employed to generate the model.

###### 

Correlation between TNM stage and other clinicopathological features and exon V expression level

  Features                               Correlation coefficient   *p* value
  -------------------------------------- ------------------------- -----------
  Histological grade (G1 or G2 vs. G3)   0.241                     0.041
  Invasion of the intestinal wall        0.488                     0.000
  Node involvement                       0.972                     0.000
  Distant metastasis                     0.534                     0.000
  Vessel invasion                        0.367                     0.002
  Exon V expression level                0.028                     0.816

Discussion {#S0010}
==========

The main aim of the presented research was to assess any prognostic value of the *FJ 194940.1* exon V expression level in colon cancer. To achieve the goal, the expression level assessed by real-time PCR was compared with established prognostic factors and survival time of patients with colorectal cancer.

The analysis conducted shows that exon V expression level is not related significantly with any clinicopathological features in this series of CRC. However, there was a visible tendency to a higher expression level of this exon in cases where tumours do not infiltrate vessels. Furthermore, high exon V expression level was associated with longer survival times. The statistical results obtained indicate that high expression levels of exon V correspond to a risk of death more than two times lower in comparison to cases with a low exon V expression level and, moreover, that the expression level influences the overall survival time independently of any established prognostic factors.

Qualitative expression analysis of the exon V *FJ 194940.1* gene transcript has not shown any correlation with clinicopathological features, or any association with survival time \[[@CIT0013]\]. Using real-time PCR, exon V relative expression level in the examined population was shown to be highly diverse, ranging from 0.02 to 18000.36. In normal human tissue, *FJ 194940.1* gene is expressed in the kidney \[[@CIT0014]\]. Unpublished data also indicate that in physiological conditions the *FJ 194940.1* gene undergoes alternative splicing. Exon V is an invariable element of all detected variants of *FJ 194940.1* in colon cancer. In accordance with the above, it is possible that during cancerogenesis the balance between splice variants of this gene is shifted and some isoforms of this gene are more specific for colon cancer. Consequently, quantitative investigation into the expression of separate elements of the *FJ 194940.1* transcript could be more useful for colon cancer prognosis.

There is a link between expression of all elements of the part B *FJ 194940.1* transcript and low-grade colon cancer \[[@CIT0013]\]. The study presented here shows links between high exon V level expression and lack of vessel infiltration and longer survival time. Exon V is an element of the part B *FJ 194940.1* transcript. Consequently, the data may suggest that some part of the *FJ 194940.1* gene could play a protective role against the spread of cancer cells and metastasis formation. The exact mechanism through which the gene could exert its effect on CRC progression remains unknown. Some elements of *FJ 194940.1* gene expression are associated with better prognosis for patients with colorectal cancer in the analysed series.

The conclusions drawn above stand in contradiction to earlier findings obtained in colon cancer cases \[[@CIT0016], [@CIT0018]\]. Balcerczak M. *et al*. \[[@CIT0018]\] suggested that expression of a fragment of the *FJ 194940.1* gene transcript in colon cancer is engaged in the process of metastasis formation and could be correlated with worse prognosis for the patient. Expression of fragments of the *FJ 194940.1* gene transcript was associated with more advanced tumours, with lymph node metastases and with distant metastases. Quantitative analysis has confirmed these observations. It has shown that the expression level of the *FJ 194940.1* gene transcript fragment was higher in cancer with metastases to lymph nodes and distant metastases. Higher levels were observed in more advanced cases, classified as III and IV according to the pTNM classification \[[@CIT0016]\].

The discrepancies described might be explained by the difference in the examined fragment of the *FJ 194940.1* transcript. The Bartczak *et al*. \[[@CIT0013]\] studies took separate exons of the *FJ 194940.1* gene into consideration, whereas Balcerczak M. *et al*. \[[@CIT0018]\] and Balcerczak E. *et al*. \[[@CIT0016]\] analysed the fragment of its transcript that consists of exon V and part of exon IV. Also, alternative pre-mRNA splicing gives the opportunity to generate multiple transcripts from a single m-RNA precursor, so it is possible to develop two isoform encoding proteins with antagonistic functions. An interesting example of cancer-related regulation by alternative splicing is the *BCL-X* gene. This gene has two splice variants: long antiapoptotic and short proapoptotic \[[@CIT0023]\]. This is caused by the dephosphorylation of SR proteins, a family of protein factors that regulate alternative splicing (known as trans-acting regulatory factors). Modifications of those proteins by dephosphorylation induce changes in the production of particular isoforms -- in this situation, increasing the level of proapoptotic splice variant with a simultaneous loss in the antiapoptotic form \[[@CIT0023], [@CIT0024]\].

*FJ 194940.1* gene expression correlates with cancer progression independently of the analysed clinicopathological parameters.
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